These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 9866424)

  • 21. Successful treatment with low dose Ara-C in de novo acute myeloid leukemia with trilineage myelodysplasia.
    Kawano F; Nishimura Y; Tsukamoto A; Satoh M; Sanada I; Shido T
    Int J Hematol; 1992 Feb; 55(1):101-2. PubMed ID: 1581580
    [No Abstract]   [Full Text] [Related]  

  • 22. Low dose cytosine arabinoside in myelodysplasia and acute myelogenous leukemia: a review.
    Bolwell BJ; Cassileth PA; Gale RP
    Leukemia; 1987 Aug; 1(8):575-9. PubMed ID: 3312846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients.
    Clavio M; Gatto S; Beltrami G; Quintino S; Canepa L; Pierri I; Galbusera V; Carrara P; Miglino M; Varaldo R; Ballerini F; Venturino C; Cerri R; Risso M; Balleari E; Carella AM; Sessarego M; Ghio R; Bacigalupo A; Gobbi M
    J Exp Clin Cancer Res; 2002 Dec; 21(4):481-7. PubMed ID: 12636093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A case of acute myelocytic leukemia in relapse controlled by continuous home administration of Ara-C].
    Takimoto Y; Imanaka F; Kouzai K; Okuhara T
    Gan To Kagaku Ryoho; 1996 Mar; 23(4):495-8. PubMed ID: 8678505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [An elderly patient with myelodysplastic syndrome successfully treated with combination of granulocyte-colony stimulating factor and continuous-drip infusion of low-dose cytarabine and etoposide].
    Yamada T; Tsurumi H; Hara T; Fukuno K; Goto H; Oyama M; Moriwaki H
    Rinsho Ketsueki; 2000 Mar; 41(3):218-21. PubMed ID: 10774251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cytarabine].
    Ota K
    Gan To Kagaku Ryoho; 1987 Oct; 14(10):2983-7. PubMed ID: 3478003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
    Russo D; Malagola M; de Vivo A; Fiacchini M; Martinelli G; Piccaluga PP; Damiani D; Candoni A; Michielutti A; Castelli M; Testoni N; Ottaviani E; Rondoni M; Pricolo G; Mazza P; Zuffa E; Zaccaria A; Raspadori D; Bocchia M; Lauria F; Bonini A; Avanzini P; Gugliotta L; Visani G; Fanin R; Baccarani M
    Br J Haematol; 2005 Oct; 131(2):172-9. PubMed ID: 16197446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Myelodysplastic syndrome and myelogenous leukemia. Treatment with low-dose cytarabine].
    Waage A; Hammerstrøm J; Lødemel B; Hoff JE; Langtind J
    Tidsskr Nor Laegeforen; 1986 Feb; 106(6):496-7. PubMed ID: 3457484
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy of low-dose cytarabine therapy in myelodysplastic syndromes.
    el-Mangoush M; Singh NK
    J Assoc Physicians India; 1992 Jul; 40(7):452-4. PubMed ID: 1484026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Small dose of ARA-C in the treatment of an elderly patient with acute myeloblastic leukemia].
    Takeyama H; Yano K; Ohoshima K; Satake T; Emi N; Sugihara T; Kawashima K
    Gan To Kagaku Ryoho; 1983 Nov; 10(11):2418-22. PubMed ID: 6579883
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Successful treatment of acute myelomonocytic leukemia developed from essential thrombocythemia with cytarabine plus etoposide].
    Ishii Y; Goto A; Katagiri T; Miyazawa K; Ohyashiki K
    Rinsho Ketsueki; 2004 Nov; 45(11):1211-3. PubMed ID: 15609690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [An aged patient with acute myelogenous leukemia complicated with liver cirrhosis: successful treatment with low-dose cytosine arabinoside].
    Saigo K; Ozaki S; Ueda K; Ryo R; Tatsumi E; Yamaguchi N
    Gan To Kagaku Ryoho; 1989 Jul; 16(7):2441-4. PubMed ID: 2751321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: intermediate dose cytarabine (2 x 1 g/m2 on days 1, 3, and 5).
    Sperr WR; Piribauer M; Wimazal F; Fonatsch C; Thalhammer-Scherrer R; Schwarzinger I; Geissler K; Knöbl P; Jäger U; Lechner K; Valent P
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):3965-71. PubMed ID: 15217926
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined low-dose cytarabine, melphalan and mitoxantrone for older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.
    Yamauchi T; Negoro E; Arai H; Ikegaya S; Takagi K; Takemura H; Inai K; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
    Anticancer Res; 2007; 27(4C):2635-9. PubMed ID: 17695426
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pericarditis induced by high-dose cytosine arabinoside chemotherapy.
    Hermans C; Straetmans N; Michaux JL; Ferrant A
    Ann Hematol; 1997; 75(1-2):55-7. PubMed ID: 9322684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over the age of 60: two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poor-risk AML.
    Bolaños-Meade J; Guo C; Gojo I; Karp JE
    Leuk Res; 2004 Jun; 28(6):571-7. PubMed ID: 15120933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
    Giles FJ; Kantarjian HM; Cortes JE; Faderl S; Verstovsek S; Thomas D; Garcia-Manero G; Wierda W; Ferrajoli A; Kornblau S; Mattiuzzi GN; Tsimberidou AM; Albitar M; O'Brien SM; Estey E
    Leuk Res; 2005 Jun; 29(6):649-52. PubMed ID: 15863204
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
    Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
    J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission.
    Stone RM; DeAngelo DJ; Janosova A; Galinsky I; Canning C; Ritz J; Soiffer RJ
    Am J Hematol; 2008 Oct; 83(10):771-7. PubMed ID: 18756547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.